TC
GILD icon

TFR Capital’s Gilead Sciences GILD Stock Holding History

TFR Capital’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$306K Buy
2,423
+98
+4% +$12.9K 0.09% 138
2026
Q1 		$324K Buy
2,325
+39
+2% +$5.46K 0.1% 130
2025
Q4 		$281K Sell
2,286
-84
-4% -$10.2K 0.09% 137
2025
Q3 		$263K Sell
2,370
-183
-7% -$20.8K 0.09% 145
2025
Q2 		$283K Buy
+2,553
New +$272K 0.1% 140

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

TFR Capital's GILD Position: Q2 2026 in Review

TFR Capital increased its Gilead Sciences (GILD) stake by 4.2% in Q2 2026, buying an estimated $12.9K and bringing the position to 2,423 shares worth $306K. The position accounts for 0.09% of the portfolio, ranked #138.

TFR Capital first reported a position in GILD in Q2 2025 and has held it in 5 quarters since. The position peaked at $324K in Q1 2026. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • TFR Capital held 2,423 shares of Gilead Sciences worth $306K as of Q2 2026.
  • TFR Capital bought 98 Gilead Sciences shares in Q2 2026, an estimated $12.9K.
  • Gilead Sciences made up 0.09% of TFR Capital's portfolio in Q2 2026, its #138 holding.
  • TFR Capital first reported a position in Gilead Sciences in Q2 2025 and has held it in 5 quarters since.
  • TFR Capital's Gilead Sciences position peaked at $324K in Q1 2026.
  • 2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on TFR Capital's 13F filing for Q2 2026, filed 6 Aug 2026.